CCR5 antagonists useful for treating AIDS

Details CCR5 antagonists useful for treating AIDS CCR5 antagonists useful for treating AIDS

2006-03-07

2006-03-07

Bernhardt, Emily (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S252110, C514S253110, C514S253130, C544S295000, C544S357000, C544S364000

Reexamination Certificate

active

07008946

ABSTRACT:
Compounds of the formulaor a pharmaceutically acceptable salt or isomer thereof, wherein:Q, X and Z are CH or N;R, R4–R7and R13are H or alkyl;R1is H, alkyl, fluoroalkyl, R9-arylalkyl, R9-heteroarylalkyl, alkyl-SO2—, cycloalkyl-SO2—, fluoroalkyl-SO2—, R9-aryl-SO2—, R9-heteroaryl-SO2—, N(R22)(R23)—SO2—, alkyl-C(O)—, cycloalkyl-C(O)—, fluoroalkyl-C(O)—, R9-aryl-C(O)—, NH-alkyl-C(O)— or R9-aryl-NH—C(O)—;R2is H and R3is H, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, R9-aryl, R9-arylalkyl, R9-heteroaryl, or R9-heteroarylalkyl, and when X and Z are each CH, R3is alkoxy, R9-aryloxy, R9-heteroaryloxy, alkylC(O)O—, alkylaminoC(O)O—, alkylC(O)NR13—, alkylOC(O)NR13— or alkylaminoC(O)NR13—;or R2and R3together are ═O, ═NOR10, ═N—NR11R12or ═CH-alkyl;R8is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenymethyl, alpha-substituted benzyl or alpha-substituted heteroarylmethyl;R9–R12are as defined;are disclosed for the treatment of HIV, solid organ transplant rejection, graft v. host disease, inflammatory diseases, atopic dermatitis, asthma, allergies or multiple sclerosis, as well as pharmaceutical compositions and combinations with antiviral or anti-inflammatory agents.

REFERENCES:
patent: 5883096 (1999-03-01), Lowe et al.
patent: 5889006 (1999-03-01), Lowe et al.
patent: 5952349 (1999-09-01), Asberom et al.
patent: 5977138 (1999-11-01), Wang et al.
patent: 6037352 (2000-03-01), Lowe et al.
patent: 6066636 (2000-05-01), Kozlowski et al.
patent: 1 103 276 (2000-06-01), None
patent: WO 94/18192 (1994-08-01), None
patent: WO 97/16440 (1997-05-01), None
patent: WO 97/24324 (1997-07-01), None
patent: WO 99/04794 (1999-02-01), None
patent: WO 00/66558 (2000-11-01), None
patent: WO 00/66559 (2000-11-01), None
Vandamme et al,Antiviral Chemistry and Chemotherapy, 9(1998) p. 187-203.
Connor et al,Virology, 206(1995) p. 935-944.
Plater-Zyberk et al,Immunol. Let., 57(1997) p. 117-120.
Boiardi et al,Clinical and Experimental Rheumatology, 17, (1999) p. 419-425.
Hatano et al,Clin. Exp. Immunol., 117(1999) p. 237-243.
Raychaudhuri et al,International J. of Immunopharmacology, 20(1998) p. 661-667.
Chihara et al,J. Allergy Clin. Immunol., 100, 6, part 2 (1997) p. S52-S55.
Beck et al,J. Immunol., 159, 6 (1997) p. 2962-72.
Tagat et al,Bioorganic&Medicinal Chemistry Letters, 11(2001) 2143-2146.
Vincenti,Amer. J. Transplantation, 2(2002) 898-903, (Abstract).
Wang et al,Rheumatology, 43(2004) 569-573.
Cook,Reviews in Neurological Diseases, 1(2004) 37-40.
Owen,Pulmonary Pharmacol.&Therapeutics, 14(2001) 193-202.
Fischereder et al,Lancet, 357(2001) 1758-1761.

Affiliated with

Also associated with

Rating

CCR5 antagonists useful for treating AIDS does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CCR5 antagonists useful for treating AIDS, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CCR5 antagonists useful for treating AIDS will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3544227